Value through Innovation26 March 2015

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 next

FDA affirms superiority of Pradaxa® (dabigatran etexilate) 150mg over warfarin in reduction of both ischaemic and haemorrhagic strokes

- For Non-US, Non-UK & Non-Canadian Media Only

Boehringer Ingelheim and Lilly to feature 30 presentations on type 1 and type 2 diabetes at the 72nd American Diabetes Association Scientific Sessions

- EX US & UK. Medical Media Only.

Afatinib* delivers unprecedented first line efficacy in patients with EGFR mutation positive lung cancer in registration trial

- For NON-US media only

Boehringer Ingelheim launches first-of-a-kind fundraising model to support disease awareness projects

- For NON-US Media Only

Boehringer Ingelheim expands development capacities with new technical centre


Boehringer Ingelheim further strengthens animal health presence in China: Manufacturing joint venture for veterinary vaccines


Jentadueto™ (linagliptin/metformin hydrochloride) tablets recommended for approval in the treatment of adults with Type 2 Diabetes in Europe

- For Non-U.S. and Non-UK Media

€100,000 in reward donations for projects fundraising to prevent atrial fibrillation-related strokes

- For NON-US Media Only

One million signatures needed to call upon World Health Organisation to save lives through education and improved management of atrial fibrillation

- For NON-US Media Only

Boehringer Ingelheim announces positive phase II results for once-daily tiotropium in asthma

- For Media outside the U.S., Canada and UK

Boehringer Ingelheim’s once-daily bronchodilator olodaterol* successfully completes Phase II clinical trial program in COPD

- For Media outside the U.S., Canada and UK

Switching to TWYNSTA® allows patients with uncontrolled hypertension on monotherapy to rapidly reach their blood pressure goals

- For Non-US and Non-UK Healthcare Media Only

Boehringer Ingelheim on growth path - Successful 2011 financial year


GLORIATM-AF Registry Program investigating use of antithrombotic therapy in 56,000 patients with atrial fibrillation at risk of stroke announced

- For non-US, UK & Canadian Media

Viral cure achieved without interferon in up to 82% of hepatitis C patients (GT-1a & -1b*)

- For media outside of the U.S.A. only

First ever data investigating interferon-free treatment in hepatitis C patients who have liver cirrhosis shows high viral cure rate

- For media outside of the U.S.A. only

Leading medical and patient organisations join forces to improve stroke prevention in atrial fibrillation

- For NON-US and NON-UK Media Only

Dabigatran etexilate (Pradaxa®) associated with significantly lower rates of fatal and traumatic intracranial haemorrhage compared with Warfarin

- For Non-US, UK & Canadia Media Only
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 next